Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: werewolftx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/3/2024 | $12.00 | Mkt Outperform | JMP Securities |
| 8/24/2023 | $9.00 | Outperform | Wedbush |
| 6/6/2023 | $11.00 → $12.00 | Buy | Jefferies |
| 11/19/2021 | $29.00 → $28.00 | Outperform | SVB Leerink |
| 9/10/2021 | $26.00 | Buy | BofA Securities |
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will participate in a fireside chat at 4:20 PM EDT on Thursday, June 5, 2025, at the Jefferies Global Healthcare Conference, taking place on June 3-5, 2025. A live webcast link for the presentation will be available at https:
There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening Skin Cancer Awareness Month in May shines a spotlight on the growing burden of advanced skin cancers The investigational drug is designed to be activated in the tumor microenvironment, including in cutaneous squamous cell carcinoma SCOTTSDALE, Ariz., May 20, 2025 (GLOBE NEWSWIRE) -- A common and unsightly skin cancer that can turn deadly has been undetectable for more than a year in a patient treated with a new targeted immune-therapy in a clinical trial at HonorHealth Research Institute. Wayne Futch, 73, of Phoenix, developed a type
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced Sameer Chopra, M.D., Ph.D., Vice President of Clinical Development, will speak during the Hanson Wade Cytokine-Based Drug Development Summit taking place May 15-16 in Boston, Massachusetts. The presentation will highlight how data from patients treated with IL-2 and IL-12 INDUKINE molecules in first-in-human clinical trials have succ
– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking to build on the clinical activity and tolerability demonstrated in the recently completed WTX-330 first-in-human Phase 1 trial – – Company announces development of its proprietary INDUCER™ T cell engager molecules; development candidate targeted by the end of the second quarter of 2025 – – Updated cash guidance provides runway into the fourth quarter of 2026 – WATERTOWN, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an in
- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production - - Findings offer a more detailed understanding of WTX-921's anti-inflammatory impact on the immune landscape in the inflamed colon - WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced a poster presentation further characterizing its conditionally-a
WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that management will participate in the following upcoming investor conferences in the month of May: The Citizens Life Sciences Conference 2025Date: Thursday, May 8, 2025 Time: 10:00am ETLocation: New York Hilton Midtown Management will participate in a fireside chat Bank of America Securities 2025 Health Care ConferenceDate: Wednes
WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting. "Steve brings deep experience in strategic transactions to Werewolf at this critical tim
WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will present a corporate overview at 1:30 PM ET on Monday, April 7, 2025, at the 24th Annual Needham Virtual Healthcare Conference, taking place on April 7–10, 2025. A live webcast link
– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half and the second half of 2025, respectively – – Plan to meet with the FDA in the second half of 2025 to discuss potential registrational pathways for both monotherapy and combination therapy for WTX-124 in select indications – – Interim data from Phase 1/1b clinical trial of WTX-124 as monotherapy and in combination with pembrolizumab anticipated to be released in the fourth quarter of 2025 – – On track to initiate Phase 1/2 dose- and regimen
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat from 11:20-11:50 AM on Tuesday, March 11, 2025, in Studio 3 at the Leerink Partners Global Biopharma Conference, taking place March 10-12, 2025, in Miami, Fl
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
JMP Securities initiated coverage of Werewolf Therapeutics with a rating of Mkt Outperform and set a new price target of $12.00
Wedbush initiated coverage of Werewolf Therapeutics with a rating of Outperform and set a new price target of $9.00
Jefferies resumed coverage of Werewolf Therapeutics with a rating of Buy and set a new price target of $12.00 from $11.00 previously
SVB Leerink reiterated coverage of Werewolf Therapeutics with a rating of Outperform and set a new price target of $28.00 from $29.00 previously
BofA Securities initiated coverage of Werewolf Therapeutics with a rating of Buy and set a new price target of $26.00
Evercore ISI Group initiated coverage of Werewolf Therapeutics with a rating of Outperform and set a new price target of $23.00
SVB Leerink initiated coverage of Werewolf Therapeutics with a rating of Outperform and set a new price target of $29.00
Jefferies initiated coverage of Werewolf Therapeutics with a rating of Buy and set a new price target of $22.00
H.C. Wainwright initiated coverage of Werewolf Therapeutics with a rating of Buy and set a new price target of $32.00
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
3 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
3 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
EFFECT - Werewolf Therapeutics, Inc. (0001785530) (Filer)
8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
SCHEDULE 13D/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
S-3 - Werewolf Therapeutics, Inc. (0001785530) (Filer)
S-8 - Werewolf Therapeutics, Inc. (0001785530) (Filer)
10-Q - Werewolf Therapeutics, Inc. (0001785530) (Filer)
8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
DEFA14A - Werewolf Therapeutics, Inc. (0001785530) (Filer)
DEF 14A - Werewolf Therapeutics, Inc. (0001785530) (Filer)
424B5 - Werewolf Therapeutics, Inc. (0001785530) (Filer)
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13D/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13D/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G - Werewolf Therapeutics, Inc. (0001785530) (Subject)
Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors relapsed or refractory to standard of care therapy, including two patients with ongoing unconfirmed partial responses (uPR) in the highest dose tested to date, cohort 4 (12 mg) - Safety data indicate WTX-124 is generally well-tolerated through cohort 4 with no dose limiting toxicities and no indication of vascular leak syndrome (VLS) or other typically severe IL-2-mediated toxicities - Preliminary data support the potential of WTX-124 to be a differentiated next-generation IL-2 compound by showing immune cell activation in the
Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor activity to be described in poster presentation.Additional posters representing an expansive body of data demonstrating the potential of Werewolf's PREDATOR™ platform and INDUKINE™ product candidates will also be presented.Company to host conference call and webcast to review WTX-124 initial clinical results November 3, 2023, at 8:30 am ET WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the d
WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting. "Steve brings deep experience in strategic transactions to Werewolf at this critical tim
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and immunological diseases, today announced the appointment of Anil Singhal, Ph.D., President and Chief Executive Officer of Trishula Therapeutics, as a member of its board of directors. "I am thrilled to join Werewolf's board of directors as the company advances its novel INDUKINE molecules through clinical development," said Dr. Singhal. "Werewolf is demonstrating the power of the PREDATORTM protein engineering p
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors. "Mike is a world-renowned oncologist and clinical researcher who has made countless contributions to the field of cancer immunotherapy. I am delighted to have Mike join our Board at this important time in the clinical development of our WTX-124 and WTX-330 INDUKINE molecules," sai
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Meeta Chatterjee, Ph.D., Senior Vice President of Global Business Development at Legend Biotech Corporation, as a member of its board of directors. "I am thrilled to join Werewolf's board of directors as the company prepares to advance investigational new drug applications for its two lead INDUKINETM product candidates, WTX-124 and WTX-330, for the treatment of solid tumors," sai
Veteran life sciences executive brings more than 30 years CMC and product development strategy expertise to rapidly advance programs and oversee manufacturing CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Chulani Karunatilake, Ph.D. as Chief Technology Officer (CTO). Dr. Karunatilake brings more than 30 years of experience in Chemistry and Manufacturing Controls (CMC) process and strategy development and will oversee manufac
CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Mike Sherman, chief executive officer of Chimerix, Inc., as a member of its board of directors. "The promise of immunotherapy has long been appreciated, but never fully realized. Werewolf has pioneered an elegant approach that may finally unleash that potential. This platform may translate to multiple drugs to address numerous challenges to treating cancers," Mr. Sherman said. "